Amica Mutual Insurance Co. Has $3.12 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Amica Mutual Insurance Co. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 108,523 shares of the biopharmaceutical company’s stock after selling 21,514 shares during the quarter. Amica Mutual Insurance Co.’s holdings in Pfizer were worth $3,124,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. MCF Advisors LLC raised its position in Pfizer by 3.7% in the third quarter. MCF Advisors LLC now owns 27,590 shares of the biopharmaceutical company’s stock worth $915,000 after purchasing an additional 975 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its stake in Pfizer by 18.5% in the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 503,170 shares of the biopharmaceutical company’s stock valued at $16,690,000 after buying an additional 78,421 shares in the last quarter. Trust Co. of Toledo NA OH grew its position in Pfizer by 2.1% in the third quarter. Trust Co. of Toledo NA OH now owns 122,829 shares of the biopharmaceutical company’s stock valued at $4,074,000 after acquiring an additional 2,567 shares during the period. JGP Wealth Management LLC raised its stake in Pfizer by 3.4% during the third quarter. JGP Wealth Management LLC now owns 60,487 shares of the biopharmaceutical company’s stock worth $2,006,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Blossom Wealth Management lifted its holdings in shares of Pfizer by 11.5% during the third quarter. Blossom Wealth Management now owns 10,943 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 1,130 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Trading Up 1.0 %

Shares of PFE stock traded up $0.25 during trading hours on Monday, reaching $25.65. The company had a trading volume of 41,630,566 shares, compared to its average volume of 41,999,020. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $145.24 billion, a price-to-earnings ratio of 71.25, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a 50 day moving average of $26.92 and a 200 day moving average of $28.31.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.